PT  - JOURNAL ARTICLE
AU  - Vasiliki-Kalliopi Bournia
AU  - George E. Fragoulis
AU  - Panagiota Mitrou
AU  - Konstantinos Mathioudakis
AU  - Anastasios Tsolakidis
AU  - George Konstantonis
AU  - Ioulia Tseti
AU  - Georgia Vourli
AU  - Maria G. Tektonidou
AU  - Dimitrios Paraskevis
AU  - Petros P. Sfikakis
TI  - Different Covid-19 Outcomes Among Systemic Rheumatic Diseases: A Nation-wide Cohort Study
AID  - 10.1101/2022.03.11.22271887
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.11.22271887
4099  - http://medrxiv.org/content/early/2022/03/12/2022.03.11.22271887.short
4100  - http://medrxiv.org/content/early/2022/03/12/2022.03.11.22271887.full
AB  - Background Nationwide data at a country level on Covid-19 in unvaccinated patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are scarce.Methods By interlinking data from national electronic registries, covering nearly 99% of the Greek population (approximately 11,000,000), between March 2020 and February 2021, when vaccination became available, we recorded confirmed infections and Covid-19-associated hospitalizations and deaths in essentially all adult patients with RA, AS, PsA, SLE, and SSc under treatment (n=74,970, median age of 67.5, 51.2, 58.1, 56.2, 62.2 years, respectively) and in individually matched (1:5) on age, sex, and region of domicile random comparators from the general population.Results Binary logistic regression analysis after adjusting for age, sex and biologic agents, revealed that RA, PsA, SLE and SSc, but not AS patients, had significantly higher risk of infection (by 43%, 25%, 20% and 49%, respectively), and hospitalization for Covid-19 (by 81%, 56%, 94%, and 111%, respectively), possibly due, at least in part, to increased testing and lower threshold for admission. Patients with RA and SSc had indeed higher Covid-19 associated mortality rates [OR:1.86 (95% CI 1.37 to 2.52) and OR:2.90 (95% CI 0.97 to 8.67), respectively] compared to the general population. Each additional year of age increased the risk of hospitalization for Covid-19 by 3% (OR 1.030, 95% CI: 1.028 to 1.034) and the risk of Covid-19 related death by 8% (OR 1.08, 95% CI: 1.07 to 1.09), independently of gender, systemic rheumatic disease, and biologic agents. A further analysis using AS patients as the reference category, adjusting again for age, sex and use of biologic agents showed that patients with SSc had increased mortality (OR: 6.90, 95% CI: 1.41 to 33.72), followed by SLE (OR: 4.05 95% CI: 0.96 to 17.12) and RA patients (OR: 3.65, 95% CI: 1.06 to 12.54), whereas PsA patients had comparable mortality risk with AS patients.Conclusion Comparing to the general population, Covid-19 may have a more severe impact in real-world patients with systemic rheumatic disease. Covid-19 related mortality is increased in subgroups of patients with specific rheumatic diseases, especially in older ones, underscoring the need for priority vaccination policies and access to targeted treatments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly supported by the Kleon Tsetis Foundation, in the context of promoting academic research initiatives within its COVID-19 response frameworkAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Data Protection Office of the Greek Ministry of Health (17 Aristotelous str, 10187, Athens, Greece, dpo{at}moh.gov.gr / gdpr{at}moh.gov.gr), gave ethical approval for this work, granting permission for the use of anonymized data deposited in the social security services (IDIKA) database and the national Covid-19 digital registry, according to the European legislation for General Data Protection Regulation, (27 April 2016) and the Greek national laws (4600/2019, 4624/2019, 3892/10, 3418/2005).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the Data Protection Officer of the Greek Ministry of Health but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Data Protection Officer of the Greek Ministry of Health.ASAnkylosing SpondylitisCIConfidence IntervalCovid-19Corona virus disease 2019DMARDsDisease Modifying Anti-Rheumatic DrugsEULAREuropean League Against RheumatismICD-10International Classification of Disease-10OROdds RatioPsAPsoriatic ArthritisRARheumatoid ArthritisSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SDStandard DeviationSLESystemic Lupus ErythematosusSRDSystemic Rheumatic DiseaseSScSystemic Sclerosis